Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
Top Cited Papers
Open Access
- 28 June 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (26) , 2684-2692
- https://doi.org/10.1056/nejmoa066584
Abstract
Information regarding the safety of selective serotonin-reuptake inhibitors (SSRIs) in human pregnancy is sparse. Concern has been raised about the risk of congenital heart defects associated with the use of SSRIs in pregnancy.Keywords
This publication has 29 references indexed in Scilit:
- Maternal use of selective serotonin re‐uptake inhibitors in early pregnancy and infant congenital malformationsBirth Defects Research Part A: Clinical and Molecular Teratology, 2007
- First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosageBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2006
- Selective Serotonin-Reuptake Inhibitors and Persistent Pulmonary Hypertension of the NewbornNew England Journal of Medicine, 2006
- Antidepressant drugs during pregnancy and infant congenital heart defectReproductive Toxicology, 2006
- Risks Associated With Selective Serotonin Reuptake Inhibitors in PregnancyObstetrics & Gynecology, 2005
- The Medical Management of DepressionNew England Journal of Medicine, 2005
- Guidelines for case classification for the national birth defects prevention studyBirth Defects Research Part A: Clinical and Molecular Teratology, 2003
- Outcomes of Prenatal Antidepressant ExposureAmerican Journal of Psychiatry, 2002
- Developmental Toxicology Studies of Fluoxetine Hydrochloride Administered Orally to Rats and RabbitsFundamental and Applied Toxicology, 1994
- Confidence Interval Estimation of InteractionEpidemiology, 1992